← Back to Patent Explorer
US4789658A Expired / Lapsed US ⏱️ 0.0 years remaining

Immunoprophylactic and immunotherapeutic agents

Assignee: Ajinomoto Co Inc
•
Filing: 1986-06-09
•
Granted: 1988-12-06
•
Expires: 2006-06-09
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An immunopropylactic and immunotherapeutic agent comprising human interleukin 2 of human cellular origin is disclosed along with a method of producing the agent.

Inventors

  • 👤 Ryota Yoshimoto
  • 👤 Nobukazu Kashima
  • 👤 Junji Hamuro
  • 👤 Koji Mitsugi

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-04 14:51
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/54; C07K14/55; A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K31/716; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61P; A61P35/00

Claims Analysis

Total Claims: 2
Claim 1
Independent Claim 86 words
An immunoprophylactic and immunotherapeutic agent, composition comprising grade E human interleukin 2 of human T-lymphocyte cell origin, which is substantially free from endotoxins and pyrogens and is wholly or partially in the oxidized state, having a specific activity of at least 2×10 5 units/mg protein, said interleukin 2 showing no cytocidal activity against human lymphocytes in vitro at a concentration of 10 5 units/ml and having substantially no other lymphokine or monokine activity, in combination with an amount of lentinan sufficient to exert synergistic immunological activity.
Claim 2
Dependent Claim 86 words
An immunoprophylactic and immunotherapeutic agent, composition comprising grade E human interleukin 2 of human T-lymphocyte cell origin, which is substantially free from endotoxins and pyrogens and is wholly or partially in the oxidized state, having a specific activity of at least 2×10 5 units/mg protein, said interleukin 2 showing no cytocidal activity against human lymphocytes in vitro at a concentration of 10 5 units/ml and having substantially no other lymphokine or monokine activity, in combination with an amount of lentinan sufficient to exert synergistic immunological activity.

References Cited (Backward Citations)

US4359389A Cited
US4368148A Cited
US4350687A Cited
US4390623A Cited
US4411992A Cited
US4406830A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1991-12-06 1992-06-06 1992-12-06 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1995-12-06 1996-06-06 1996-12-06 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1999-12-06 2000-06-06 2000-12-06 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag